A compound of Formula I, or a pharmaceutically acceptable salt thereof, or a stereoisomer thereof, or a pharmaceutically acceptable salt of the stereoisomer thereof: wherein the burn is 0, 1, 2, 3 or 4； n is 0, 1, 2, 3, 4 or 5, p is 0, 1 or 2； q is 0, 1, 2, 3 or 4； t is 0, 1, 2, 3, 4 or 5； X is -CO- or -SO2 -； And is selected from the group consisting of: (1) C1-C5 alkanediyl, C2-C5 alkenodiyl, and C2-C5 alkynediyl, wherein each of alkanediyl, alkenodiyl and alkynediyl is optionally substituted with one to three groups that are independently selected from halogen, -ORa15, -S (O) p-C1-C3 alkyl； (2) - (CRaRa) jQ- (CRaRa) k, in which jyk are integers that are independently selected from 0, 1 and 2, (3) a bond, and (4) phenylene optionally substituted with one to three groups which are independently selected from R120； Z is selected from the group consisting of: (1) phenyl, (2) a 5- or 6-membered heterocyclic ring, with 1 to 4 heteroatoms that are selected from oxygen, sulfur and nitrogen, (3) a benzene ring condensed with a C5-C10 carbocyclic ring, (4) a 5- or 6-membered heterocyclic ring, with 1 to 4 heteroatoms selected from oxygen, sulfur and nitrogen fused to a 5-heterocyclic ring or 6 members, with 1 to 4 heteroatoms that are selected from oxygen, sulfur and nitrogen, and (5) a 5 or 6 member heterocyclic ring, with 1 to 4 heteroatoms that are selected from oxygen, sulfur and nitrogen condensed with a C5-C10 carbocyclic ring； R1 is selected from the group consisting of: (1) alkyl C1-C5 optionally substituted with 1 to 5 halogen atoms, (2) C3-C6 cycloalkyl, (3) halogen, (4) nitro, (5) cyano, (6) -C (O) Ra, (7) -C (O) 2Ra, (8) -C (O) NRaRb, and (9) -QRb40； R2 is selected from the group consisting of halogen and C1-C5 alkyl； R3 is selected from the group consisting of: (1) C1-C6 alkyl optionally substituted with 1 to 5 groups which are independently selected from halogen, -ORa, -CO2Ra, and -CONRaRb, (2) - (CH2) t-phenyl or - (CH2) tO-phenyl , and wherein said phenyl i
